vTv Therapeutics
VTVT
24 hedge funds and large institutions have $1.65M invested in vTv Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
20% more funds holding
Funds holding: 20 → 24 (+4)
0% less ownership
Funds ownership: 0.11% → 0.11% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
37% less capital invested
Capital invested by funds: $2.6M → $1.65M (-$955K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$149K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.6K |
| 3 |
Millennium Management
New York
|
+$6.48K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.17K |
| 5 |
Comerica Bank
Dallas,
Texas
|
+$611 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$32.6K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.18K |
| 4 |
BlackRock
New York
|
-$880 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$98 | +4 | +133% |
|
VTVT Hedge Fund Activity: Q3 2023 in Review
24 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2023, worth a combined $1.65M — down 37% from $2.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTVT positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Pathstone Family Office, opening a new position worth an estimated $149K. The largest seller was Susquehanna International Group, cutting an estimated $34.2K.
- 24 institutional investors held vTv Therapeutics (VTVT) as of Q3 2023, up from 20 in Q2 2023.
- Funds reported $1.65M of vTv Therapeutics stock for Q3 2023, down 37% quarter-over-quarter.
- 6 funds opened new vTv Therapeutics positions in Q3 2023 and 2 closed out, a net change of +4 holders.
- The largest vTv Therapeutics buyer in Q3 2023 was Pathstone Family Office, an estimated $149K added.
- The largest vTv Therapeutics seller in Q3 2023 was Susquehanna International Group, an estimated $34.2K sold.
Based on aggregated 13F filings for Q3 2023.